Adjuvant therapy in melanoma adopted as standard of care

Public summary

I have been closely involved with a number of major initiatives that have defined the standard of care and new treatments for high risk melanoma. These have ranged from being senior investigator on a large phase 3 trial, key contributor to published individual patient data meta-analysis, key contributor to pivotal clinical trials, submitted grant application to CRUK for new biomarker driven trial and developing further new international trial with EORTC and Pharma.

Impact date	1 Jan 2015
Category of impact	Health and wellbeing
Impact level	Engagement